Kamila M Bond1, Joshua D Hughes2, Amanda L Porter1, Josiah Orina2, Shanna Fang3, Ian F Parney4. 1. School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2. Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: parney.ian@mayo.edu.
Abstract
INTRODUCTION: Pilocytic astrocytoma is a classically benign tumor that most often affects pediatric patients. Rarely, it occurs during adulthood. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA) to examine the clinical presentation, extent of resection, and recurrence rate associated with this tumor in this population. MATERIALS AND METHODS: Our institutional records were retrospectively reviewed for cases of pilocytic astrocytoma in adults. A PubMed search identified English-language studies of pathology-proven APA. A meta-analysis was performed to determine the relationship between extent of tumor resection and recurrence. RESULTS: Forty-six patients with APA were diagnosed at our institution (mean age 33.6 ± 13.3; 24 [52%] female). Twenty-four patients (52%) underwent gross total resection, 11 (24%) subtotal resection, 4 (9%) near total resection, 4 (9%) observation after biopsy, and 3 (6%) radiotherapy alone. Tumors recurred or progressed in 6 (13%) patients, of whom 4 were treated by STR and 2 were treated by radiotherapy alone. Thirty-nine (95%) patients were still alive at last follow-up. A systematic literature review identified 415 patients with APA in 38 studies. Including our case series, 7 studies reported extent of resection, follow-up, and recurrence. Of 254 patients with a weighted mean follow-up of 77.7 ± 49.6 (31-250) months, 129 (51%) were treated with gross total resection, and 125 (49%) underwent subtotal resection. Tumor recurred in 79 (31%) patients, 22 (27%) after gross total resection and 57 (73%) after subtotal resection (P < 0.001). CONCLUSIONS: Pilocytic astrocytoma rarely presents during adulthood. Overall, prognosis is favorable and survival rates are high. APA recurrence is more likely after STR, and the goal of surgery should always be GTR when feasible.
INTRODUCTION:Pilocytic astrocytoma is a classically benign tumor that most often affects pediatric patients. Rarely, it occurs during adulthood. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA) to examine the clinical presentation, extent of resection, and recurrence rate associated with this tumor in this population. MATERIALS AND METHODS: Our institutional records were retrospectively reviewed for cases of pilocytic astrocytoma in adults. A PubMed search identified English-language studies of pathology-proven APA. A meta-analysis was performed to determine the relationship between extent of tumor resection and recurrence. RESULTS: Forty-six patients with APA were diagnosed at our institution (mean age 33.6 ± 13.3; 24 [52%] female). Twenty-four patients (52%) underwent gross total resection, 11 (24%) subtotal resection, 4 (9%) near total resection, 4 (9%) observation after biopsy, and 3 (6%) radiotherapy alone. Tumors recurred or progressed in 6 (13%) patients, of whom 4 were treated by STR and 2 were treated by radiotherapy alone. Thirty-nine (95%) patients were still alive at last follow-up. A systematic literature review identified 415 patients with APA in 38 studies. Including our case series, 7 studies reported extent of resection, follow-up, and recurrence. Of 254 patients with a weighted mean follow-up of 77.7 ± 49.6 (31-250) months, 129 (51%) were treated with gross total resection, and 125 (49%) underwent subtotal resection. Tumor recurred in 79 (31%) patients, 22 (27%) after gross total resection and 57 (73%) after subtotal resection (P < 0.001). CONCLUSIONS:Pilocytic astrocytoma rarely presents during adulthood. Overall, prognosis is favorable and survival rates are high. APA recurrence is more likely after STR, and the goal of surgery should always be GTR when feasible.
Authors: Matthew W Parsons; Nicholas S Whipple; Matthew M Poppe; Joe S Mendez; Donald M Cannon; Lindsay M Burt Journal: J Neurooncol Date: 2020-10-31 Impact factor: 4.130
Authors: Jacopo Falco; Julius Höhne; Morgan Broggi; Emanuele Rubiu; Francesco Restelli; Ignazio G Vetrano; Marco Schiariti; Elio Mazzapicchi; Giulio Bonomo; Paolo Ferroli; Karl-Michael Schebesch; Francesco Acerbi Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738
Authors: Omer Sager; Ferrat Dincoglan; Selcuk Demiral; Bora Uysal; Hakan Gamsiz; Esra Gumustepe; Fatih Ozcan; Onurhan Colak; Ahmet Tarik Gursoy; Cemal Ugur Dursun; Ahmet Oguz Tugcu; Galip Dogukan Dogru; Rukiyye Arslan; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu Journal: World J Exp Med Date: 2022-05-20
Authors: Devin McBride; Zaid Aljuboori; Eyas M Hattab; Richard Downs; Shiao Woo; Brian Williams; Joseph Neimat; Eric Burton Journal: BMC Cancer Date: 2018-08-09 Impact factor: 4.430
Authors: Jiri Bartek; Sanjay Dhawan; Erik Thurin; Ali Alattar; Sasha Gulati; Bertil Rydenhag; Roger Henriksson; Clark C Chen; Asgeir Store Jakola Journal: J Neurooncol Date: 2020-05-19 Impact factor: 4.130